Hypomethylating agents for patients with myelodysplastic syndrome
Editorial Group: Cochrane Haematological Malignancies Group
Published Online: 5 OCT 2011
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Bauer K, Hutzschenreuter F, Skoetz N, Kreuzer KA, Monsef I, Engert A. Hypomethylating agents for patients with myelodysplastic syndrome (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009340. DOI: 10.1002/14651858.CD009340.
- Publication Status: New
- Published Online: 5 OCT 2011
This is the protocol for a review and there is no abstract. The objectives are as follows:
The main objective of this systematic review is to evaluate the role of hypomethylating agents (that is 5-Aza, DAC) for patients with MDS. For this purpose we will critically, systematically and statistically analyse the efficacy of hypomethylating agents compared to best supportive care or no treatment as well as to other agents or chemotherapy regimens with regard to overall survival (OS), treatment-related mortality (TRM), complete response rate (CR), progression-free survival (PFS) or similar outcomes, quality of life, adverse events and the time to transformation to AML.